ten23 health, a company based in Basel and Visp, and Ypsomed announced that they are entering into a strategic partnership to advance the commercialization of the YpsoDose wearable injector for subcutaneous self- injection of large-volume doses. Both parties will proactively invest in technology and infrastructure to offer the YpsoDose patch injector platform as a fully integrated solution for the subcutaneous self- administration of large volume injectables.
This comprehensive solution includes a ready-to-use cartriQ glass cartridge from SCHOTT Pharma as the primary packaging for the drug, the YpsoDose patch injector platform from Ypsomed, and formulation and process development, filling, assembly, and testing (QC) of the final product by ten23 health. Pharmaceutical customers will have the option to receive a rigorously tested and documented overall solution, which will significantly accelerate time to clinic, and subsequently time to market, allowing them to concentrate on their core initiatives.
This collaboration will harness ten23 health’s expertise in the development, manufacturing and testing of complex formulations for subcutaneous administration while leveraging their comprehensive experience in the clinical and commercial fill & finish of complex dosage forms, including large volume cartridges for devices. ten23 health is well positioned to meet specific and unique requirements.
“Exciting partnership”
“This exciting partnership with Ypsomed aligns seamlessly with our vision of a successful drug product in which the drug-device integration is taken into account from the very beginning of its design – where formulation, primary packaging, and medical devices are equally important parts, providing stable, safe, usable and effective medicines to patients,” says Prof. Dr. Hanns-Christian Mahler, Chief Enablement Officer at ten23 health.
Ypsomed’s platform enables its customers to havevconsiderable freedom in thevchoice of components and partners to implement their own processes as needed. The integrated solution provided by the collaborating partners allows them to leverage knowledge and to collaborate throughout all necessary steps and components for an overall shortened time-to-market and reduced development risks of the biopharmaceutical drug/device combination product.
“Together with ten23 as strong partner, we offer a comprehensive solution, for our customers to bring their medicines to market as a commercially viable and competitive product in a short time, at a lower cost and with low risks,” says Reto Jost, Category Lead Large Volume Injectors at Ypsomed.
Further information
on Ypsomed: www.ypsomed.com
and on ten23 Health: www.ten23.health
Source: Press release
